These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 1978484

  • 1. Biochemical pharmacology of the atypical neuroleptic remoxipride.
    Köhler C, Hall H, Magnusson O, Lewander T, Gustafsson K.
    Acta Psychiatr Scand Suppl; 1990; 358():27-36. PubMed ID: 1978484
    [Abstract] [Full Text] [Related]

  • 2. Regional distribution and in vivo binding of the atypical antipsychotic drug remoxipride. A biochemical and autoradiographic analysis in the rat brain.
    Köhler C, Radesäter AC, Karlsson-Boethius G, Bryske B, Widman M.
    J Neural Transm Gen Sect; 1992; 87(1):49-62. PubMed ID: 1531593
    [Abstract] [Full Text] [Related]

  • 3. Remoxipride, a new potential antipsychotic compound with selective antidopaminergic actions in the rat brain.
    Ogren SO, Hall H, Köhler C, Magnusson O, Lindbom LO, Angeby K, Florvall L.
    Eur J Pharmacol; 1984 Jul 20; 102(3-4):459-74. PubMed ID: 6149133
    [Abstract] [Full Text] [Related]

  • 4. Effects of chronic neuroleptic treatment on agonist affinity states of the dopamine-D2 receptor in the rat brain.
    Hall H, Sällemark M.
    Pharmacol Toxicol; 1987 May 20; 60(5):359-63. PubMed ID: 2886988
    [Abstract] [Full Text] [Related]

  • 5. Effects of remoxipride and some related new substituted salicylamides on rat brain receptors.
    Hall H, Sällemark M, Jerning E.
    Acta Pharmacol Toxicol (Copenh); 1986 Jan 20; 58(1):61-70. PubMed ID: 2869639
    [Abstract] [Full Text] [Related]

  • 6. Distribution of remoxipride to the human brain and central D2-dopamine receptor binding examined in vivo by PET.
    Farde L, von Bahr C.
    Acta Psychiatr Scand Suppl; 1990 Jan 20; 358():67-71. PubMed ID: 1978494
    [Abstract] [Full Text] [Related]

  • 7. Neuropharmacological and behavioural properties of remoxipride in the rat.
    Ogren SO, Florvall L, Hall H, Magnusson O, Angeby-Möller K.
    Acta Psychiatr Scand Suppl; 1990 Jan 20; 358():21-6. PubMed ID: 1978483
    [Abstract] [Full Text] [Related]

  • 8. Subchronic treatment of rats with remoxipride fails to modify sigma binding sites in the brain.
    Ericson H, Ross SB.
    Eur J Pharmacol; 1992 Jun 05; 226(2):157-61. PubMed ID: 1353452
    [Abstract] [Full Text] [Related]

  • 9. [Selective antidopaminergic properties of remoxiprid, a new potential antipsychotic agent].
    Ogren SO, Hall H, Köhler C, Magnusson O, Florvall L.
    Arzneimittelforschung; 1985 Jun 05; 35(8):1227-31. PubMed ID: 2866774
    [Abstract] [Full Text] [Related]

  • 10. The dopamine D2 antagonist remoxipride acts in vivo on a subpopulation of dopamine D2 receptors.
    Ogren SO, Rosén L, Fuxe K.
    Neuroscience; 1994 Jul 05; 61(2):269-83. PubMed ID: 7969908
    [Abstract] [Full Text] [Related]

  • 11. Binding characteristics of remoxipride and its metabolites to dopamine D2 and D3 receptors.
    Mohell N, Sällemark M, Rosqvist S, Malmberg A, Högberg T, Jackson DM.
    Eur J Pharmacol; 1993 Jul 06; 238(1):121-5. PubMed ID: 8405075
    [Abstract] [Full Text] [Related]

  • 12. The discovery of epidepride and its analogs as high-affinity radioligands for imaging extrastriatal dopamine D(2) receptors in human brain.
    de Paulis T.
    Curr Pharm Des; 2003 Jul 06; 9(8):673-96. PubMed ID: 12570798
    [Abstract] [Full Text] [Related]

  • 13. Effects of the dopamine D2 selective receptor antagonist remoxipride on dopamine turnover in the rat brain after acute and repeated administration.
    Magnusson O, Mohringe B, Thorell G, Lake-Bakaar DM.
    Pharmacol Toxicol; 1987 May 06; 60(5):368-73. PubMed ID: 2886989
    [Abstract] [Full Text] [Related]

  • 14. Hypotensive and bradycardic effects elicited by spinal dopamine receptor stimulation: effects of D1 and D2 receptor agonists and antagonists.
    Pellissier G, Demenge P.
    J Cardiovasc Pharmacol; 1991 Oct 06; 18(4):548-55. PubMed ID: 1724532
    [Abstract] [Full Text] [Related]

  • 15. Effects of remoxipride's metabolites on dopamine D2 receptors and receptor functions in the rat.
    Ogren SO, Hall H, Widman M, Angeby-Möller K.
    Pharmacol Toxicol; 1993 Dec 06; 73(6):325-34. PubMed ID: 8153056
    [Abstract] [Full Text] [Related]

  • 16. Regional in vivo binding of the substituted benzamide [3H]eticlopride in the rat brain: evidence for selective labelling of dopamine receptors.
    Köhler C, Hall H, Gawell L.
    Eur J Pharmacol; 1986 Jan 21; 120(2):217-26. PubMed ID: 3948920
    [Abstract] [Full Text] [Related]

  • 17. Specific in vitro and in vivo binding of 3H-raclopride. A potent substituted benzamide drug with high affinity for dopamine D-2 receptors in the rat brain.
    Köhler C, Hall H, Ogren SO, Gawell L.
    Biochem Pharmacol; 1985 Jul 01; 34(13):2251-9. PubMed ID: 4015674
    [Abstract] [Full Text] [Related]

  • 18. Dopamine receptors in canine caudate nucleus.
    Maeno H.
    Mol Cell Biochem; 1982 Mar 19; 43(2):65-80. PubMed ID: 6123940
    [Abstract] [Full Text] [Related]

  • 19. Dopamine D2 receptors and dopamine metabolism. Relationship between biochemical and behavioural effects of substituted benzamide drugs.
    Magnusson O, Fowler CJ, Köhler C, Ogren SO.
    Neuropharmacology; 1986 Feb 19; 25(2):187-97. PubMed ID: 2939362
    [Abstract] [Full Text] [Related]

  • 20. Comparison of the effects of haloperidol, remoxipride and raclopride on "pre"- and postsynaptic dopamine receptors in the rat brain.
    Magnusson O, Fowler CJ, Mohringe B, Wijkström A, Ogren SO.
    Naunyn Schmiedebergs Arch Pharmacol; 1988 Apr 19; 337(4):379-84. PubMed ID: 2900472
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.